What’s the Buzz?! Accelerating Innovation: The Persephoni Way

Join us for an insightful session of What’s the Buzz?! featuring special guests Hilary Schultz, MS, CEO of Persephoni BioPartners, and William Heath, Ph.D., CSO at Persephoni BioPartners. Together, they will share how Persephoni’s innovative model guides early-stage biotech companies from conception to clinical stages, rivaling the internal R&D processes of large pharmaceutical companies. Discover how their collaborative approach accelerates growth, blending the agility of early academic spinouts with the robust development frameworks of established pharma.

RSVP now on LinkedIn: https://www.linkedin.com/events/what-sthebuzz-acceleratinginnov7267649975273099264/theater/

About Hilary Schulz:
Hilary Schulz, MS, is an internationally recognized serial entrepreneur with a dynamic background spanning private equity, venture capital, biotechnology, and academic-to-industry company formation. As CEO of Persephoni BioPartners, Hilary leverages her deep expertise to foster early-stage biotech innovation.

A Harvard-trained molecular biologist with a Master’s in Biomedicine and Business from Drexel University, Hilary has driven transformative growth in life sciences. She was instrumental in scaling Nucleate Bio’s accelerator program, supporting expansion to 18 global regions and contributing to ventures that collectively raised over $170 million. At Persephoni, Hilary has built essential partnerships and leadership teams, aiming to secure $100 million in venture funding to fuel Philadelphia’s biotech ecosystem. Recognized among the Top 100 entrepreneurs and innovators of 2023, Hilary continues to champion impactful biotech advancements.

About William (Bill) Heath, Ph.D.:
Dr. William Heath brings over 36 years of leadership in pharmaceutical discovery, development, and commercialization across multiple therapeutic areas. As CSO at Persephoni BioPartners, Bill applies his extensive experience to advance early-stage biotech companies through strategic development frameworks.

A Ph.D. graduate from The Rockefeller University with postdoctoral studies at Harvard Medical School, Bill’s illustrious career includes pivotal roles at Eli Lilly, where he spearheaded biotherapeutics initiatives and led global R&D efforts. As Group Vice President at Lilly Research Laboratories, he managed multi-site teams, driving innovation and the launch of several successful medicines. Bill’s commitment to scientific excellence, diversity, and mentorship has made him a respected figure in the industry, passionate about guiding the next generation of biotech leaders.